• Tyra Biosciences released initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC.
• Data supported meaningful tumor responses, with activity strongest in patients with minimal disease, underpinning a planned adjuvant Phase 3 strategy.
• Safety profile appeared suitable for chronic dosing, with limited severe treatment-related events and no major class-related toxicities highlighted.
• Development plan calls for completing the 60 mg once-daily cohort, starting a 70 mg cohort for higher-burden disease, then aligning Phase 3 design.
• Results were already presented in the release, with a management conference call scheduled today to discuss the findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609090700PR_NEWS_USPR_____LA42613) on September 09, 2026, and is solely responsible for the information contained therein.